Khaddour K.; Jonna S.; Deneka A.; Patel J.D.; Abazeed M.E.; Golemis E.; Borghaei H.; Boumber Y.
(2021)
Epidermal growth factor receptor-targeting tyrosine kinase inhibitors (EGFR TKIs) are the standard of care for patients with EGFR-mutated metastatic lung cancer. While EGFR TKIs have initially high response rates, inherent ...